Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Dr.Zhen Cao, Pharmaceutical Policy and Regulation ,Best Researcher Award

Dr.Zhen Cao, Pharmaceutical Policy and Regulation ,Best Researcher Award

Dr.Zhen Cao, at School of Public Health, Capital Medical University,China

Author Profile

Academic and Professional Background 🌟

Cao Zhen is a dedicated doctoral candidate at the School of Public Health, Capital Medical University, specializing in health policy and hospital management. With a robust academic foundation, Cao Zhen is a valued member of the Expert Pool for Project Funding Supervision at the National Health Commission. Her impressive track record includes overseeing two provincial and ministerial-level projects, participation in a National Social Science Foundation project, and contributing to numerous other provincial and ministerial-level initiatives. Her scholarly contributions are evidenced by the publication of nine academic papers in reputable journals.

 


Research and Innovations 🔬📊

  • Completed/Ongoing Research Projects: 15
  • Consultancy/Industry Projects: 2
  • Journals Published (SCI, Scopus, etc.): 9
  • Patents Published/Under Process: 2
  • Collaborations: Notably collaborated with the National Health Commission of the People’s Republic of China during the COVID-19 pandemic to study funding and material support for epidemic prevention and control, as well as the economic operation of hospitals. This collaboration provided crucial decision-making support to tackle pandemic-related challenges.

Professional Memberships 🏅

  • People’s Republic of China Health and Wellness Commission
  • Project Funding Supervision Expert Pool

Research Areas 🔍

  • Hospital Management
  • Health Policy

 

🎓Publication Top Noted:

Paper Title :Adenylyl cyclase localization to the uropod of aggregating Dictyostelium cells requires RacC
    • Authors: Sherly I Celada, Guoliang Li, Lindsay J Celada, Wenfu Lu, Thanigaivelan Kanagasabai, Weiran Feng, Zhen Cao, Nazifa Salsabeel, Ninghui Mao, LaKendria K Brown, Zaniya A Mark, Michael G Izban, Billy R Ballard, Xinchun Zhou, Samuel E Adunyah, Robert J Matusik, Xiaofei Wang, Zhenbang Chen
    • Journal: Molecular Oncology
    • Year:2023
    • Citations : 3

     

Paper Title :Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
  • Authors: Thomas Wiesner, William Lee, Anna C Obenauf, Leili Ran, Rajmohan Murali, Qi Fan Zhang, Elissa WP Wong, Wenhuo Hu, Sasinya N Scott, Ronak H Shah, Iñigo Landa, Julia Button, Nathalie Lailler, Andrea Sboner, Dong Gao, Devan A Murphy, Zhen Cao, Shipra Shukla, Travis J Hollmann, Lu Wang, Laetitia Borsu, Taha Merghoub, Gary K Schwartz, Michael A Postow, Charlotte E Ariyan, James A Fagin, Deyou Zheng, Marc Ladanyi, Klaus J Busam, Michael F Berger, Yu Chen, Ping Chi
  • Journal: Nature
  • Year:2015
  • Citations : 240
Paper Title : Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth
  • Authors: Leili Ran, Inna Sirota, Zhen Cao, Devan Murphy, Yuedan Chen, Shipra Shukla, Yuanyuan Xie, Michael C Kaufmann, Dong Gao, Sinan Zhu, Ferdinando Rossi, John Wongvipat, Takahiro Taguchi, William D Tap, Ingo K Mellinghoff, Peter Besmer, Cristina R Antonescu, Yu Chen, Ping Chi
  • Journal: Cancer discovery
  • Year:2015
  • Citations :130
Paper Title :SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
  • Authors:Ping Mu, Zeda Zhang, Matteo Benelli, Wouter R Karthaus, Elizabeth Hoover, Chi-Chao Chen, John Wongvipat, Sheng-Yu Ku, Dong Gao, Zhen Cao, Neel Shah, Elizabeth J Adams, Wassim Abida, Philip A Watson, Davide Prandi, Chun-Hao Huang, Elisa De Stanchina, Scott W Lowe, Leigh Ellis, Himisha Beltran, Mark A Rubin, David W Goodrich, Francesca Demichelis, Charles L Sawyers
  • Journal:Science
  • Year: 2017
  • Citations :905
Paper Title : Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
  • Authors: Zeda Zhang, Chuanli Zhou, Xiaoling Li, Spencer D Barnes, Su Deng, Elizabeth Hoover, Chi-Chao Chen, Young Sun Lee, Yanxiao Zhang, Choushi Wang, Lauren A Metang, Chao Wu, Carla Rodriguez Tirado, Nickolas A Johnson, John Wongvipat, Kristina Navrazhina, Zhen Cao, Danielle Choi, Chun-Hao Huang, Eliot Linton, Xiaoping Chen, Yupu Liang, Christopher E Mason, Elisa de Stanchina, Wassim Abida, Amaia Lujambio, Sheng Li, Scott W Lowe, Joshua T Mendell, Venkat S Malladi, Charles L Sawyers, Ping Mu
  • Journal: Cancer cell
  • Year: 2020
  • Citations : 114